100488-87-7 Usage
Uses
1. Used in Pharmaceutical Research:
CV-6209 is used as a competitive PAF receptor antagonist for studying the role of PAF receptor signaling in various biological processes and diseases.
2. Used in Platelet Aggregation Inhibition:
CV-6209 is used as an inhibitor of PAF-induced human platelet aggregation, which can be beneficial in understanding and treating conditions related to abnormal platelet aggregation.
3. Used in Cardiovascular Research:
CV-6209 is used to inhibit PAF-induced hypotension and lethality in rats, providing insights into the management of cardiovascular conditions associated with PAF receptor activation.
4. Used in Toxicology and Safety Studies:
CV-6209 is employed to investigate the effects of PAF receptor antagonism on hypotension triggered by various substances, such as arachidonic acid, histamine, bradykinin, or isoproterenol, which can be crucial in assessing the safety and potential side effects of PAF receptor antagonists in drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 100488-87-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,0,4,8 and 8 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 100488-87:
(8*1)+(7*0)+(6*0)+(5*4)+(4*8)+(3*8)+(2*8)+(1*7)=107
107 % 10 = 7
So 100488-87-7 is a valid CAS Registry Number.
InChI:InChI=1/C34H59N3O6.ClH/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-19-20-22-25-35-33(39)42-28-32(41-4)29-43-34(40)37(30(3)38)27-31-24-21-23-26-36(31)6-2;/h21,23-24,26,32H,5-20,22,25,27-29H2,1-4H3;1H
100488-87-7Relevant articles and documents
Platelet activating factor antagonists: Synthesis and structure-activity studies of novel PAF analogues modified in the phosphorylcholine moiety
Takatani,Yoshioka,Tasaka,Terashita,Imura,Nishikawa,Tsushima
, p. 56 - 64 (2007/10/02)
New analogues of platelet activating factor (PAF), in which the phosphate and trimethylammonium moieties were replaced with an acylcarbamoyl moiety and a quaternary cyclic ammonium group, were synthesized. Their biological activities as PAF antagonists we